Greywolf's New Drug Reawakens Immune System in Hard-to-Treat Cancers

OXFORD, United Kingdom – June 02, 2026 – As a former market analyst now navigating the equally complex data sets of school schedules and grocery budgets, it takes a special kind of corporate announcement to make me pause. This week, a small biotech company from Oxford did just that. At the American Society of Clinical Oncology (ASCO) annual meeting, a major event in the cancer research world, Greywolf Therapeutics presented data that offers a tangible sliver of hope for patients who are running out of options.

The company announced promising results for its experimental drug, GRWD5769. When combined with an existing immunotherapy, it showed it could shrink tumors in patients whose cancers had learned to evade the very treatments designed to save them. For these patients, and for those with specific cancers that never responded to immunotherapy in the first place, this is more than just data—it’s the potential for more time.

The Numbers That Offer New Hope

At the heart of the announcement are the results from the EMITT-1 clinical trial. The study tested GRWD5769, an oral pill, in combination with cemiplimab, a standard immunotherapy drug known as a PD-1 inhibitor. The trial focused on patients with six different types of advanced solid tumors who had two things in common: they had been heavily treated before, and their cancer had become resistant to drugs like cemiplimab.

The numbers, while early, are compelling. The combination therapy achieved objective response rates (ORR)—meaning a measurable shrinkage of tumors—between 13% and 36% across the different cancer types. For context, once a patient’s cancer becomes resistant to a PD-1 inhibitor, the chance of responding to another similar treatment is often in the single digits. Seeing response rates in the double digits is a significant signal.

Looking deeper into the data presented, we see:

• Urothelial (bladder) cancer: 36% of patients saw their tumors shrink.
• Non-small cell lung cancer (NSCLC): A 21% response rate, but more impressively, 55% of patients achieved “durable clinical benefit,” meaning their disease was controlled for at least six months. The median progression-free survival was 33 weeks, a remarkable duration in this setting.
• Microsatellite stable colorectal cancer (MSS-CRC): This result is perhaps the most significant. MSS-CRC is notoriously “cold,” meaning it’s invisible to the immune system and stubbornly resistant to immunotherapy. In this group, the combination achieved a 17% response rate and an impressive 51% durable clinical benefit. For a cancer type where immunotherapy has largely failed, this is a crucial first step.

Professor Fiona Thistlethwaite, the trial's principal investigator, captured the sentiment perfectly. “What excites me about this trial is the combination of what we’re seeing - strong signals of efficacy across six tumor types that have shown great resistance to immunotherapy, with very few side effects,” she stated. “That's unusual at such an early stage.” The therapy was reported to be well-tolerated, a critical factor for patients who have already endured multiple rounds of harsh treatments.

Unmasking Tumors: A Clever Scientific Disguise

So how does it work? This is where Greywolf’s innovative science comes into play. From my analyst days, I know that a truly disruptive technology often rethinks a problem from a new angle. That’s what Greywolf appears to have done.

Think of the immune system’s T-cells as a police force on the hunt for cancer cells. These T-cells identify criminals by the “wanted posters”—or antigens—displayed on the cell surface. Cancers, however, are masters of disguise. An enzyme called ERAP1 can act like a faulty editor, trimming and altering these wanted posters until they are unrecognizable. The T-cell police force floats right by, unable to see the threat.

GRWD5769 is a first-in-class inhibitor of ERAP1. It essentially blocks this faulty editor. By doing so, it forces the cancer cell to display a new and different set of wanted posters, making it visible to the immune system once again. This process reawakens the body’s natural defenses.

The synergy with cemiplimab is the other half of the story. PD-1 inhibitors like cemiplimab work by taking the brakes off T-cells, giving them the green light to attack. But if the T-cells can't see the target, releasing the brakes is useless. GRWD5769 makes the cancer visible, and cemiplimab empowers the T-cells to attack. It’s a classic one-two punch.

“Seeing the combination of strong durable clinical benefit rates and sustained PFS in a population that had already failed anti-PD-1 therapy... is a clinically meaningful signal,” said Tom Lillie, Greywolf’s Chief Medical Officer. The data validates a mechanism that scientists have found compelling for years but had yet to prove in the clinic.

A Small Biotech with Big Ambitions

For Greywolf Therapeutics, these results are a major validation of its core scientific platform. As a clinical-stage company, positive data is the currency that fuels progress, attracting investment and potential partners. The company is already advancing the drug into the next stage of trials to inform a larger, randomized study that regulators will want to see.

Peter Joyce, Greywolf's CEO, highlighted the broader implication: “We believe this data positions GRWD5769 as a genuinely differentiated approach to two of the largest unmet needs in oncology — T cell exhaustion and tumor visibility to the immune system.”

This isn't just about one drug. Greywolf is building a platform around antigen modulation, with other programs in its pipeline targeting autoimmune diseases. This diversification, coupled with a strategic collaboration with the makers of cemiplimab for the trial, paints a picture of a company with a clear vision and a methodical plan for execution. From a market perspective, Greywolf has just moved from a company with a promising idea to one with promising clinical data, a transition that fundamentally changes its value and position in the fiercely competitive biotech landscape.

The Road Ahead: Cautious Optimism

While the excitement is palpable, it’s important to maintain perspective. This is, after all, a Phase 1b study with a relatively small number of patients in each group. The results are encouraging, but they are not definitive proof. As one independent oncologist not involved with the study noted anonymously, “The mechanism is elegant and the early data is impressive, especially in MSS-CRC. But the real test will be in larger, randomized Phase 2 trials. We need to see these signals confirmed before we can declare a new standard of care.”

Greywolf is already on that path. The company is moving forward with cohort expansions to gather more data. The journey from a promising early-stage trial to an approved drug on the market is long and fraught with challenges. But for patients with advanced, resistant cancers, every step forward on that path matters. The data from the EMITT-1 trial is more than just numbers on a slide; it's a carefully plotted map pointing toward a new direction of hope.